BMS-955176

DRUG9 trials

Sponsors

ViiV Healthcare

Conditions

HIV InfectionsInfection, Human Immunodeficiency Virus

Phase 1

Relative Bioavailability Study With BMS-955176

CompletedNCT02095886

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2014-03-25End: 2014-07-07Updated: 2017-09-11

Study of Combined Oral Contraceptive Effects in Female Subjects

CompletedNCT02157467

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2014-06-02End: 2014-08-25Updated: 2018-04-17

Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.

CompletedNCT02206711

ViiV HealthcareHIV Infections

Start: 2014-08-08End: 2014-09-09Updated: 2018-04-17

Food Effect Study With BMS-955176

CompletedNCT02273947

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2014-10-23End: 2016-08-15Updated: 2017-04-17

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

CompletedNCT02578277

ViiV HealthcareHIV Infections

Start: 2015-11-09End: 2015-12-23Updated: 2018-07-13

Taste Properties of HIV Inhibitor

CompletedNCT02608918

ViiV HealthcareHIV Infections

Start: 2016-01-05End: 2016-05-24Updated: 2018-04-17

Phase 2

Study to Evaluate a HIV Drug for the Treatment of HIV Infection

CompletedNCT01803074

ViiV HealthcareHIV Infections, Infection, Human Immunodeficiency Virus

Start: 2013-04-04End: 2014-11-29Updated: 2019-11-25

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

TerminatedNCT02386098

ViiV HealthcareHIV Infections

Start: 2015-07-08End: 2017-06-07Updated: 2018-08-20

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

TerminatedNCT02415595

ViiV HealthcareInfection, Human Immunodeficiency Virus

Start: 2015-05-12End: 2017-08-21Updated: 2018-09-19

Related Papers

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial

PLoS ONE2018-10-2343 citations

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)

Clinical Infectious Diseases2017-03-1623 citations